The approval marks the start of human testing for the experimental vaccine, which is designed to strengthen immune protection in respiratory tract.

Announced completion of dose exploration portion of ORIC-944 Phase 1b clinical trial and presented data that continues to demonstrate potential best-in-class efficacy and safety Bolstered leadership ...